Abstract
Progress in the knowledge of the pathophysiology of portal hypertension has disclosed new targets for therapy, resulting in a larger spectrum of drugs with a potential role for clinical practice. This review focuses on pharmacologic treatments already available for reducing portal pressure and summarizes drugs currently under investigation in this field.
Keywords:
Chronic liver disease; Drug therapy; Hepatic resistance; Portal pressure; Splanchnic blood flow.
Copyright © 2014 Elsevier Inc. All rights reserved.
MeSH terms
-
Adrenergic alpha-1 Receptor Antagonists / therapeutic use
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiogenesis Inhibitors / therapeutic use
-
Anti-Bacterial Agents / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Antioxidants / therapeutic use
-
Carbazoles / therapeutic use
-
Carvedilol
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypertension, Portal / drug therapy*
-
Hypertension, Portal / physiopathology
-
Liver Circulation / drug effects
-
Lypressin / analogs & derivatives
-
Lypressin / therapeutic use
-
Portal Pressure / drug effects
-
Propanolamines / therapeutic use
-
Renin-Angiotensin System / drug effects
-
Somatostatin / analogs & derivatives
-
Somatostatin / therapeutic use
-
Splanchnic Circulation / drug effects
-
Terlipressin
-
Vascular Resistance / drug effects
-
Vasodilator Agents / therapeutic use
Substances
-
Adrenergic alpha-1 Receptor Antagonists
-
Adrenergic beta-Antagonists
-
Angiogenesis Inhibitors
-
Anti-Bacterial Agents
-
Antihypertensive Agents
-
Antioxidants
-
Carbazoles
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Propanolamines
-
Vasodilator Agents
-
Carvedilol
-
Lypressin
-
Somatostatin
-
Terlipressin